| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alberto Halabe Buca. Donepezil (aricept) as a treatment for anorexia nervosa: a very feasible therapeutic possibility. Expert opinion on investigational drugs. vol 18. issue 5. 2010-01-11. PMID:19388874. |
donepezil is a drug that been proven to be effective in the treatment of dementia, including alzheimer's; it has been used for affective disorders and its mechanism of action is to inhibit the acetylcholinesterase enzyme to increase acetylcholine. |
2010-01-11 |
2023-08-12 |
Not clear |
| Barbara Borroni, Mario Grassi, Chiara Costanzi, Marta Bianchi, Alessandro Padovan. Behavioral dimensions and acetylcholinesterase inhibitor-related effect in Alzheimer disease over time: a latent trajectory modeling. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. vol 22. issue 4. 2010-01-05. PMID:19996874. |
behavioral dimensions and acetylcholinesterase inhibitor-related effect in alzheimer disease over time: a latent trajectory modeling. |
2010-01-05 |
2023-08-12 |
Not clear |
| Barbara Borroni, Mario Grassi, Chiara Costanzi, Marta Bianchi, Alessandro Padovan. Behavioral dimensions and acetylcholinesterase inhibitor-related effect in Alzheimer disease over time: a latent trajectory modeling. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. vol 22. issue 4. 2010-01-05. PMID:19996874. |
to evaluate whether treatment with acetylcholinesterase inhibitors (acheis) exerts a favorable effect on the behavioral dimensions in alzheimer disease (ad) over time. |
2010-01-05 |
2023-08-12 |
Not clear |
| Mireille Basselin, Henry N Nguyen, Lisa Chang, Jane M Bell, Stanley I Rapopor. Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats. Journal of Alzheimer's disease : JAD. vol 17. issue 2. 2009-12-16. PMID:19363262. |
donepezil, an acetylcholinesterase (ache) inhibitor used for treating alzheimer's disease patients, is thought to act by increasing brain extracellular acetylcholine (ach), and ach binding to cholinergic receptors. |
2009-12-16 |
2023-08-12 |
rat |
| Bruno Vellas, Lutz Froelich, C Sampai. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Value therapy for Alzheimer's disease--a European perspective. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 3. issue 3. 2009-12-14. PMID:19595930. |
after a short review of european medicines agency (emea) committee for medicinal products for human use (chmp) recommendations for the development of medications for alzheimer's disease, we focus on the evidence with respect to cost and benefits obtained so far with acetylcholinesterase inhibitor (achei) and memantine in the treatment of alzheimer's disease. |
2009-12-14 |
2023-08-12 |
human |
| Galina F Makhaeva, Alexey Y Aksinenko, Vladimir B Sokolov, Olga G Serebryakova, Rudy J Richardso. Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorganic & medicinal chemistry letters. vol 19. issue 19. 2009-11-30. PMID:19717305. |
acetylcholinesterase and butyrylcholinesterase inhibitors are potential cognition enhancers in alzheimer disease. |
2009-11-30 |
2023-08-12 |
Not clear |
| R H Pietrzak, P Maruff, P J Snyde. Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil. The journal of nutrition, health & aging. vol 13. issue 3. 2009-11-03. PMID:19262966. |
to demonstrate this approach we examined the cognitive effects of a single acute dose administration of an acetylcholinesterase inhibitor, donepezil, in healthy older adults and in older adults with mild alzheimer's disease (ad). |
2009-11-03 |
2023-08-12 |
Not clear |
| Dmitriy Chekmarev, Vladyslav Kholodovych, Sandhya Kortagere, William J Welsh, Sean Ekin. Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharmaceutical research. vol 26. issue 9. 2009-11-02. PMID:19603258. |
acetylcholinesterase (ache) is both a therapeutic target for alzheimer's disease and a target for organophosphorus, carbamates and chemical warfare agents. |
2009-11-02 |
2023-08-12 |
Not clear |
| Shigeki Moriguchi, Norifumi Shioda, Feng Han, Jay Z Yeh, Toshio Narahashi, Kohji Fukunag. Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Hippocampus. vol 19. issue 9. 2009-10-30. PMID:19253410. |
galantamine, a novel alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nachr) in the brain. |
2009-10-30 |
2023-08-12 |
rat |
| Yu-fang Shi, Hai-yan Zhang, Wei Wang, Yan Fu, Yu Xia, Xi-can Tang, Dong-lu Bai, Xu-chang H. Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta pharmacologica Sinica. vol 30. issue 8. 2009-10-22. PMID:19578388. |
to design novel bifunctional derivatives of huperzine b (hupb) based on the concept of dual binding site of acetylcholinesterase (ache) and evaluate their pharmacological activities for seeking new drug candidates against alzheimer's disease (ad). |
2009-10-22 |
2023-08-12 |
Not clear |
| Xi-yuan Zheng, Zi-jia Zhang, Gui-xin Chou, Tao Wu, Xue-mei Cheng, Chang-hong Wang, Zheng-tao Wan. Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC- bioautographic assay. Archives of pharmacal research. vol 32. issue 9. 2009-10-15. PMID:19784581. |
acetylcholinesterase inhibitors (acheis) currently form the basis of the newest drugs available for the treatment of alzheimer's disease. |
2009-10-15 |
2023-08-12 |
Not clear |
| H R Girisha, J N Narendra Sharath Chandra, Sriramamurthy Boppana, Manish Malviya, C T Sadashiva, Kanchugarakoppal S Rangapp. Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylcholinesterase. European journal of medicinal chemistry. vol 44. issue 10. 2009-10-14. PMID:19493592. |
hypocholinergic function associated with alzheimer's disease (ad) is well-accepted hypothesis, in this regard, many research attempts have been made to elevate the reduced cholinergic neurotransmission, among them two main treatment strategies were widely explored, namely stimulation of muscarinic receptor 1 and/or reversible inhibition of acetylcholinesterase (ache) enzyme. |
2009-10-14 |
2023-08-12 |
rat |
| Ramanna V Rajesh, Loganathan Chitra, Paul G Layer, Rathanam Boopath. The aryl acylamidase activity is much more sensitive to Alzheimer drugs than the esterase activity of acetylcholinesterase in chicken embryonic brain. Biochimie. vol 91. issue 9. 2009-10-14. PMID:19607873. |
the aryl acylamidase activity is much more sensitive to alzheimer drugs than the esterase activity of acetylcholinesterase in chicken embryonic brain. |
2009-10-14 |
2023-08-12 |
chicken |
| Li Zhou, Yu-Wei Liu, Robert W Peoples, Min Yang, Xiang Tian, Yong-Xun Ai, Yuan-Ping Pang, Zhi-Wang Li, Yi-Fan Han, Chao-Ying L. Mechanism of bis(7)-tacrine inhibition of GABA-activated current in cultured rat hippocampal neurons. Neuropharmacology. vol 57. issue 1. 2009-10-01. PMID:19393253. |
bis(7)-tacrine is a novel dimeric acetylcholinesterase inhibitor derived from tacrine that shows promise for the treatment of alzheimer's disease. |
2009-10-01 |
2023-08-12 |
rat |
| Atsushi Tanaka, Shoichi Koga, Yoshihiro Hiramats. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Internal medicine (Tokyo, Japan). vol 48. issue 14. 2009-10-01. PMID:19602789. |
acetylcholinesterase inhibitors (achis) are widely used in the treatment of mild-to-moderate alzheimer's disease (ad), but their cholinergic effects could generate adverse side effects in the cardiovascular system. |
2009-10-01 |
2023-08-12 |
Not clear |
| Runa S Naik, Joachim Hartmann, Cornelia Kiewert, Ellen G Duysen, Oksana Lockridge, Jochen Klei. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. vol 12. issue 1. 2009-09-25. PMID:19470293. |
alzheimer s disease is characterized by a dysfunction of central cholinergic systems and is treated by inhibitors of acetylcholinesterase (ache). |
2009-09-25 |
2023-08-12 |
mouse |
| Jae Kyeom Kim, Heyri Bae, Mi-Jeong Kim, Soo Jung Choi, Hong Yon Cho, Han-Joon Hwang, Young Jun Kim, Seung Taik Lim, Eun Ki Kim, Hye Kyung Kim, Bok Yong Kim, Dong-Hoon Shi. Inhibitory effect of Poncirus trifoliate on acetylcholinesterase and attenuating activity against trimethyltin-induced learning and memory impairment. Bioscience, biotechnology, and biochemistry. vol 73. issue 5. 2009-08-28. PMID:19420715. |
various native korean plants were screened to find an effective acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease (ad). |
2009-08-28 |
2023-08-12 |
Not clear |
| Hailin Zheng, Moussa B H Youdim, Mati Fridki. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. Journal of medicinal chemistry. vol 52. issue 14. 2009-08-25. PMID:19485411. |
site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for alzheimer's therapy. |
2009-08-25 |
2023-08-12 |
Not clear |
| Bai-Song Wang, Hao Wang, Zhao-Hui Wei, Yan-Yan Song, Lu Zhang, Hong-Zhuan Che. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. Journal of neural transmission (Vienna, Austria : 1996). vol 116. issue 4. 2009-06-09. PMID:19221692. |
efficacy and safety of natural acetylcholinesterase inhibitor huperzine a in the treatment of alzheimer's disease: an updated meta-analysis. |
2009-06-09 |
2023-08-12 |
Not clear |
| Kamalakaran Anand Solomon, Srinivasan Sundararajan, Veluchamy Abiram. QSAR studies on N-aryl derivative activity towards Alzheimer's disease. Molecules (Basel, Switzerland). vol 14. issue 4. 2009-06-05. PMID:19384276. |
a quantitative structure activity relationship (qsar) study has been an attempted on a series of 88 n-aryl derivatives which display varied inhibitory activity towards both acetylcholinesterase (ache) and butyrylcholinesterase (bche), targets in alzheimer's drug discovery. |
2009-06-05 |
2023-08-12 |
Not clear |